Anixa Biosciences, Inc.ANIXNASDAQ
Loading
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -127.20% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -127.20% | +0.00% |
| Weighted Average Shares Growth | +2.39% | +0.90% | +1.32% | +1.74% | +3.24% |
| Weighted Average Shares Diluted Growth | +2.39% | +0.90% | +1.32% | +1.74% | +3.24% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | -100.00% | -100.00% | -100.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -25.48% | -30.29% | -22.95% | -25.52% | -19.43% |
| Book Value per Share Growth | -29.14% | -32.59% | -24.77% | -25.49% | -18.19% |
| Debt Growth | +41.98% | +48.32% | -10.13% | -12.07% | -16.09% |
| R&D Expense Growth | +15.05% | -31.32% | -45.19% | -22.63% | -28.99% |
| SG&A Expenses Growth | -18.38% | +0.84% | -17.16% | +2.79% | -12.00% |